A nurse is caring for a client who is receiving vancomycin by IV infusion over 30 min. Which of the following findings indicate the clien experiencing a vancomycin infusion reaction?

D) Oxycodone causes central nervous system depression: Oxycodone is an opioid analgesic that acts centrally on the central nervous system (CNS) to relieve pain. One of the most significant side effects of opioids like oxycodone is respiratory depression, which occurs due to the suppression of the CNS, particularly in the brainstem respiratory centers. The brainstem regulates respiratory rate and rhythm, and when opioids depress these centers, it can lead to decreased respiratory drive, resulting in a decrease in respiratory rate. A respiratory rate of 8/min is significantly below the normal range, indicating respiratory depression caused by oxycodone.

A) Oxycodone inhibits prostaglandin synthesis: Oxycodone does not directly inhibit prostaglandin synthesis. Prostaglandins are lipid compounds with various physiological effects, including inflammation and pain modulation. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, inhibit prostaglandin synthesis by blocking cyclooxygenase enzymes. However, oxycodone primarily acts on opioid receptors in the CNS to relieve pain, rather than through prostaglandin inhibition.

B) Oxycodone promotes vasodilation of cranial arteries: While opioids can cause peripheral vasodilation, particularly in large doses, the primary mechanism of action of oxycodone is not through the promotion of vasodilation of cranial arteries. Vasodilation may occur as a side effect of opioid use, but it is not the primary cause of respiratory depression associated with oxycodone.

C) Oxycodone blocks the sodium channel suspending nerve conduction: This statement describes the mechanism of action of local anesthetics, such as lidocaine, which block sodium channels to inhibit nerve conduction. However, oxycodone is not a sodium channel blocker. Its analgesic effects result from binding to opioid receptors in the CNS, particularly mu-opioid receptors, rather than blocking sodium channels. Therefore, this option is not the pathophysiology for the respiratory rate of 8/min observed in the client receiving oxycodone.

B) Melena: Melena refers to black, tarry stools and is indicative of upper gastrointestinal bleeding. Warfarin is an anticoagulant medication that works by inhibiting the synthesis of vitamin K-dependent clotting factors, thereby prolonging the time it takes for blood to clot. While anticoagulation is intended to prevent thrombosis, it also increases the risk of bleeding, including gastrointestinal bleeding. Melena is a concerning sign of significant bleeding and requires prompt medical attention. The nurse should prioritize reporting melena to the provider to facilitate further evaluation and management, which may include adjusting the warfarin dosage or investigating the underlying cause of the bleeding.

A) Hair loss: Hair loss, or alopecia, is a known side effect of warfarin but is generally not considered a priority finding compared to signs of active bleeding. While hair loss can be distressing for clients, it is typically not life-threatening and may resolve spontaneously or with discontinuation of the medication.

C) Abdominal cramping: Abdominal cramping can occur for various reasons, including gastrointestinal upset or other gastrointestinal issues, but it is not typically associated with warfarin use. While the nurse should assess and address the client's abdominal cramping, it is not as urgent as reporting signs of active bleeding such as melena.

D) Fever: Fever may indicate the presence of an infection or inflammatory process but is not directly related to warfarin therapy. However, if the fever is accompanied by signs of bleeding or other concerning symptoms, it should be reported to the provider for further evaluation. Nonetheless, in the absence of other significant symptoms, fever alone may not be as urgent as reporting melena, which suggests active bleeding.